|
Efalizumab
resources
|
|
|
|
|
|
DRUG INFO
Efalizumab
Drug Name:
Efalizumab
Indication: For treatment of psoriasis
Pharmacology: Lymphocyte activation and trafficking to skin play a role in the pathophysiology of chronic plaque psoriasis. In psoriatic skin, ICAM-1 cell surface expression is upregulated on endothelium and keratinocytes. Raptiva inhibits the binding of LFA-1 to the intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion of leukocytes to other cell types.
Mechanism Of Action: Raptiva binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result Raptiva decreases cell surface expression of CD11a.
Drug Category: Immunomodulatory Agents; Immunosupressants
Brand Names/Synonyms: Raptiva; hu1124; antiCD11 alpha; anti alphaL integrin; Raptiva (Genentech Inc)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Humanized anti-CD11a antibody
Chemical Formula: Not Available
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00074
CAS Registry Number: 214745-43-3
|
|
|
|
|
|
Efalizumab News
(When available)
Genentech Announces Full Year and Fourth Quarter 2005 Results Jan 10, 2006
MSN Money US sales of RAPTIVA(R) (efalizumab) in 2005 increased 51 percent to $79.2 million from $52.4 million in 2004. Fourth quarter ...
PDL Shares Slip on Genentech Results Jan 11, 2006
MSN Money PDL also receives payments on Genentech's Herceptin, a breast cancer therapy, its Xolair asthma drug and the Raptiva psoriasis treatment. ...
Genentech's Shares Fall On Disappointing Avastin Sales Jan 11, 2006
BioWorld Online (subscription), Immunology products Xolair (omalizumab) and Raptiva (efalizumab) had fourth-quarter sales of $93.3 million (compared to $60.3 million) and $20.4 million ...
Dead kangaroos don’t bounce, do they? Jan 14, 2006
Business Online, ...development. The company markets eight recombinant products – Rebif, Gonal-f, Saizen, Serostim, Ovidrel, Luveris, Zorbtive and Raptiva. ...
PDL Grants Patent Licenses to Merck for Humanized Antibodies ... Jan 3, 2006
PR Newswire (press release), Companies currently holding patent licenses for marketed products are Genentech, Inc. (Herceptin(R), Xolair(R), Raptiva(R) and Avastin(TM)); MedImmune, Inc. ...
Genentech Announces Full Year and Fourth Quarter 2005 Results Jan 10, 2006
Yahoo! News (press release) US sales of RAPTIVA® (efalizumab) in 2005 increased 51 percent to $79.2 million from $52.4 million in 2004. Fourth quarter RAPTIVA ...
Serono Completes Second Phase III Trial of its Proprietary ... Jan 8, 2006
Yahoo! News (press release) The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ...
XOMA Announces Commencement of Exchange Offer Jan 11, 2006
Genetic Engineering News, XOMA has a royalty interest in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed to treat moderate-to-severe plaque psoriasis. ...
XOMA Announces Senior Management Appointments Jan 12, 2006
Genetic Engineering News, ...diseases. XOMA has a royalty interest in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. ...
Biologic drugs the latest psoriasis weapon Dec 20, 2005
United Press International It as well as Amevive, Enbrel, Humira and Raptiva have been approved to treat psoriasis and psoriatic arthritis since 2003, the newspaper reported. ...
Serono Completes Second Phase III Trial of its Proprietary ... Jan 8, 2006
PR Newswire (press release), Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R). In ...
New Drugs Offer More Choices for Psoriasis Dec 21, 2005
Spartanburg Herald Journal (subscription), ...for psoriatic arthritis or psoriasis include Remicade; alefacept, sold as Amevive; etanercept, sold as Enbrel; efalizumab, sold as Raptiva; and adalimumab ...
|
|
|
